WO2020105270A1 - Filtre sanguin - Google Patents

Filtre sanguin

Info

Publication number
WO2020105270A1
WO2020105270A1 PCT/JP2019/037009 JP2019037009W WO2020105270A1 WO 2020105270 A1 WO2020105270 A1 WO 2020105270A1 JP 2019037009 W JP2019037009 W JP 2019037009W WO 2020105270 A1 WO2020105270 A1 WO 2020105270A1
Authority
WO
WIPO (PCT)
Prior art keywords
glass
mass
nonwoven fabric
blood
parts
Prior art date
Application number
PCT/JP2019/037009
Other languages
English (en)
Japanese (ja)
Inventor
智紀 兵藤
克矩 伊藤
健一 山元
Original Assignee
日東電工株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2019160327A external-priority patent/JP2020085887A/ja
Application filed by 日東電工株式会社 filed Critical 日東電工株式会社
Publication of WO2020105270A1 publication Critical patent/WO2020105270A1/fr

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

Definitions

  • the present invention relates to a blood filter.
  • a glass fiber layer composed of a glass fiber layer having an average diameter of 0.2 to 5 ⁇ and a density of 0.1 to 0.5 g / cm 3 has been proposed (for example, Patent Document 1). See 1.).
  • the present invention provides a blood filter capable of reducing the filtration time of blood while sufficiently ensuring the required separation performance.
  • the present invention [1] comprises a glass non-woven fabric and a hemagglutination agent adhered to the glass non-woven fabric, and the pressure loss value of the glass non-woven fabric with respect to the thickness of the glass non-woven fabric is 120 Pa / mm or more and 1500 Pa / mm or less.
  • the adhered amount of the hemagglutination agent includes a blood filter that is 0.1 part by mass or more and 6.6 parts by mass or less with respect to 100 parts by mass of the glass fiber contained in the glass nonwoven fabric.
  • the present invention [2] includes the blood filter according to the above [1], wherein the amount of the hemagglutination agent attached to the glass nonwoven fabric satisfies the following formulas (1) and (2).
  • y represents the adhesion amount [parts by mass] of the hemagglutination agent to 100 parts by mass of the glass fibers contained in the glass nonwoven fabric.
  • X represents the thickness of the glass nonwoven fabric. The pressure loss value [Pa / mm] of the glass nonwoven fabric is shown.
  • the pressure loss value of the glass non-woven fabric with respect to the thickness of the glass non-woven fabric (hereinafter, referred to as pressure loss / thickness) is not less than the above lower limit, and the adhered amount of the blood cell aggregating agent to the glass fiber (hereinafter, aggregating agent).
  • the amount of adhered is more than the above lower limit, so that the separation performance of the blood filter can be sufficiently ensured.
  • the pressure loss / thickness of the glass nonwoven fabric is less than or equal to the above upper limit and the amount of the aggregating agent attached is less than or equal to the above upper limit, it is possible to improve the blood filtration rate in the blood filter.
  • the pressure loss value (pressure loss / thickness) of the glass non-woven fabric with respect to the thickness of the glass non-woven fabric, and the adhesion amount of the hemagglutination agent (aggregation agent adhesion amount) to 100 parts by mass of the glass fiber The graph which shows the correlation of is shown.
  • the blood filter is capable of removing blood cells from blood and separating plasma by filtering blood.
  • the blood filter includes a glass non-woven fabric and a hemagglutination agent attached to the glass non-woven fabric.
  • the glass non-woven fabric has a sheet shape (flat plate shape) formed by intertwining glass fibers, specifically, has a predetermined thickness and extends in a direction orthogonal to the thickness direction.
  • the glass non-woven fabric includes glass fibers intertwined with each other and voids located between the glass fibers.
  • the void is a space other than glass fiber in the glass non-woven fabric, and is opened on the front and back surfaces of the glass non-woven fabric so as to communicate with the external space of the glass non-woven fabric.
  • the glass non-woven fabric may further contain a binder that bonds the glass fibers together.
  • binder examples include synthetic resins excluding the below-mentioned cationic polymer, and specifically, thermosetting resins (for example, epoxy resin, urethane resin, melamine resin, phenol resin, etc.), thermoplastic resins (for example, Examples thereof include acrylic resin, vinyl acetate resin, ethylene-vinyl acetate copolymer (EVA), vinyl chloride resin, etc.).
  • thermosetting resins for example, epoxy resin, urethane resin, melamine resin, phenol resin, etc.
  • thermoplastic resins for example, Examples thereof include acrylic resin, vinyl acetate resin, ethylene-vinyl acetate copolymer (EVA), vinyl chloride resin, etc.
  • -Binders can be used alone or in combination of two or more.
  • binders acrylic resin is preferable.
  • the content ratio of the binder is, for example, 1.0 part by mass or more, preferably 3.0 parts by mass or more, for example, 10.0 parts by mass or less, and preferably 8.0 parts by mass with respect to 100 parts by mass of the glass fiber. Below the section.
  • the average diameter of the glass fibers in such a glass nonwoven fabric is, for example, 0.1 ⁇ m or more, preferably 0.2 ⁇ m or more, for example, 10 ⁇ m or less, preferably 5 ⁇ m or less.
  • the basis weight of the glass nonwoven fabric is, for example, 10 g / m 2 or more, preferably 20 g / m 2 or more, for example, 300 g / m 2 or less, preferably 150 g / m 2 or less.
  • the pressure loss value of the glass nonwoven fabric is, for example, 20 Pa or more, preferably 30 Pa or more, more preferably 50 Pa or more, for example 600 Pa or less, preferably 350 Pa or less.
  • the pressure loss value can be measured according to the method described in Examples described later (the same applies hereinafter).
  • the thickness of the nonwoven glass fabric is, for example, 0.05 mm or more, preferably 0.10 mm or more, for example 1.0 mm or less, preferably 0.70 mm or less.
  • the thickness of the glass nonwoven fabric can be measured with a micrometer according to the method described in JIS P8118.
  • the pressure loss / thickness in the glass nonwoven fabric is an index of the roughness of the glass nonwoven fabric, and is 120 Pa / mm or more, preferably 200 Pa / mm or more, more preferably 400 Pa / mm or more, and particularly preferably 500 Pa / mm. mm or more and 1500 Pa / mm or less, preferably 1150 Pa / mm or less, and more preferably 1000 Pa / mm or less.
  • the pressure loss / thickness is above the above lower limit, it is possible to surely improve the separation performance of the blood filter, and if the pressure loss / thickness is below the above upper limit, surely reduce the blood filtration time by the blood filter. Can be achieved.
  • a hemagglutination agent is capable of aggregating blood cells in blood, and separates blood cell aggregates and plasma.
  • the hemagglutination agent may be impregnated in the binder of the glass non-woven fabric, or may be attached to the surface of the glass fiber.
  • hemagglutination agents include cationic polymers.
  • the cationic polymer is a polymer having a cationic group, and has, for example, an amino group and / or a quaternary ammonium salt group as the cationic group.
  • cationic polymers examples include amino group-containing polymers, quaternary ammonium salt group-containing polymers, amino group / quaternary ammonium salt group-containing polymers, and the like.
  • amino group-containing polymer examples include polylysine (eg, poly-L-lysine, poly-D-lysine, poly-D, L-lysine, etc.), polyallylamine, polyalanine, poly (N, N-dimethylaminoethyl ( (Meth) acrylate), a copolymer of N, N-dimethylaminoethyl (meth) acrylate and methyl (meth) acrylate, and polyethyleneimine.
  • the (meth) acrylate contains methacrylate and / or acrylate.
  • Examples of the quaternary ammonium salt group-containing polymer include poly (diallyldimethylammonium chloride) and poly (1,1-dimethyl-3,5-dimethylenepiperidinium chloride).
  • polymers having both amino groups and quaternary ammonium bases include copolymers of poly (diallyldimethylammonium chloride) and acrylamide.
  • cationic polymers preferably, a quaternary ammonium salt group-containing polymer is used, and more preferably, poly (diallyldimethylammonium chloride) is used.
  • the weight average molecular weight (Mw) of the cationic polymer is, for example, 100,000 or more, preferably 400,000 or more, for example, 10 million or less, preferably 4 million or less, more preferably 1 million or less.
  • the weight average molecular weight can be measured by GPC (gel permeation chromatograph) and calculated in terms of standard polyethylene glycol (the same applies hereinafter).
  • cationic polymers examples include Unisense FPA-1001L (poly (diallyldimethylammonium chloride), Mw: 500,000 manufactured by Senka Co.), Unisense FPA-1002L (poly (diallyldimethylammonium chloride), Mw: 900,000). , Senka Co., Ltd., C508 (poly (diallyldimethylammonium chloride), Mw: 3.5 million, manufactured by MT Aqua Polymer Co., Ltd.) and the like.
  • Such hemagglutination agents can be used alone or in combination of two or more kinds.
  • the adhesion amount of the hemagglutination agent is 0.1 parts by mass or more, preferably 0.5 parts by mass or more, 6.6 parts by mass with respect to 100 parts by mass of the glass fiber contained in the glass nonwoven fabric.
  • the amount is preferably 5.0 parts by mass or less, more preferably 4.5 parts by mass or less.
  • the amount of the aggregating agent attached can be measured according to the method described in Examples below (the same applies hereinafter).
  • the amount of adhered coagulant is above the above lower limit, it is possible to surely improve the separation performance of the blood filter, and if the amount of adhered coagulant is below the above upper limit, it is sure to reduce the filtration time of blood by the blood filter. Can be achieved.
  • the coagulant adhesion amount if the pressure loss / thickness in the glass nonwoven fabric is increased, the coagulant adhesion amount is reduced, and if the pressure loss / thickness in the glass nonwoven fabric is decreased, the coagulant adhesion amount is increased. By adjusting so as to achieve excellent balance, excellent separation performance and reduction of filtration time can be secured.
  • the amount of the aggregating agent attached is preferably 0.1 part by mass or more and 2 parts by mass or less.
  • the amount of the aggregating agent attached is preferably 0.5 parts by mass or more and 4.5 parts by mass or less.
  • the amount of the aggregating agent attached is preferably 1.0 part by mass or more and 6.6 parts by mass or less, more preferably 5.
  • the amount of the aggregating agent attached is preferably 1.4 parts by mass or more and 6.6 parts by mass or less.
  • the amount of the aggregating agent attached is set so as to satisfy the following formulas (1) and (2) in consideration of pressure loss / thickness.
  • y represents the adhesion amount [parts by mass] of the hemagglutination agent with respect to 100 parts by mass of the glass fiber contained in the glass nonwoven fabric.
  • X represents the thickness of the glass nonwoven fabric with respect to the thickness of the glass nonwoven fabric. Indicates the pressure loss value [Pa / mm].)
  • the above formula (1) shows the lower limit of the coagulant adhesion amount
  • the above formula (2) shows the upper limit of the coagulant adhesion amount. If the adhered amount of the coagulant satisfies the above formula (1) and the above formula (2), excellent separation performance and reduction in filtration time can be ensured in a more balanced manner.
  • the coagulant adhesion amount satisfies the following formula (3).
  • the glass nonwoven fabric may be impregnated with the above-mentioned binder so as to have the above-mentioned content ratio.
  • the aggregating agent liquid contains the above-described hemagglutination agent and a solvent.
  • the solvent examples include water and methanol, and preferably water.
  • the solvent can be used alone or in combination of two or more kinds.
  • the aggregating agent liquid is prepared as an aggregating agent aqueous solution in which the hemagglutination agent is dissolved in water.
  • the immersion temperature of the glass nonwoven fabric in the flocculant liquid is, for example, 5 ° C. or higher, preferably 15 ° C. or higher, for example, 50 ° C. or lower, preferably 30 ° C. or lower.
  • the immersion time of the glass nonwoven fabric in the flocculant liquid is, for example, 30 seconds or more, preferably 1 minute or more, for example, 10 minutes or less, preferably 5 minutes or less.
  • the concentration of the hemagglutination agent in the aggregating agent solution is, for example, 0.001% by mass or more, preferably 0.005% by mass or more, for example, 2.0% by mass or less, and preferably 0.5% by mass or less. ..
  • the amount of the flocculant adhered can be appropriately adjusted.
  • the glass non-woven fabric can be directly immersed in the hemagglutination agent which is liquid at room temperature.
  • the blood coagulant adheres to the glass non-woven fabric and the blood filter is manufactured.
  • the pressure loss / thickness of the glass non-woven fabric is not less than the above lower limit, and the amount of adhered coagulant is not less than the above lower limit. Therefore, the separation performance of the blood filter can be sufficiently ensured.
  • the pressure loss / thickness of the glass nonwoven fabric is less than or equal to the above upper limit, and the amount of the coagulant attached is less than or equal to the above upper limit. Therefore, the blood filtration rate in the blood filter can be improved.
  • the blood filter can be used alone, or can be used by laminating another filter (for example, a porous membrane made of resin) on the blood filter.
  • another filter for example, a porous membrane made of resin
  • the blood filter can be suitably used for blood filtration for various purposes.
  • blood filters include blood filters for genetic tests, blood filters for infectious disease tests, blood filters for biochemical tests, blood filters for microbiological tests, and the like.
  • Glass fibers and an aqueous dispersion of an acrylic resin as a binder were prepared, and glass nonwoven fabrics A to J were prepared by a wet papermaking method.
  • the average diameter of the glass fibers in the glass nonwoven fabric A was 2.7 ⁇ m, and the content ratio of the binder was 5.7 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric A was 52 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric B was 3.4 ⁇ m, and the content ratio of the binder was 5.5 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric B was 55 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric C was 1.9 ⁇ m, and the content ratio of the binder was 5.5 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric C was 52 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric D was 2.7 ⁇ m, and the content ratio of the binder was 6.0 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric D was 31 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric E was 2.7 ⁇ m, and the content ratio of the binder was 5.9 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric E was 101 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric F was 1.5 ⁇ m, and the content ratio of the binder was 6.7 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric F was 58 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric G was 1.7 ⁇ m, and the content ratio of the binder was 5.8 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric G was 51 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric H was 4.0 ⁇ m, and the content ratio of the binder was 5.9 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric H was 54 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric I was 3.5 ⁇ m, and the content ratio of the binder was 5.4 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric I was 55 g / m 2 .
  • the average diameter of the glass fibers in the glass nonwoven fabric J was 3.7 ⁇ m, and the content ratio of the binder was 5.3 parts by mass with respect to 100 parts by mass of the glass fibers.
  • the basis weight of the glass nonwoven fabric J was 56 g / m 2 .
  • the respective thicknesses of the glass nonwoven fabrics A to J are shown in Tables 1 and 2.
  • the concentration of the coagulant liquid A was 0.05% by mass
  • the concentration of the coagulant liquid B was 0.005% by mass
  • the concentration of the coagulant liquid C was 0.5% by mass.
  • Unisense FPA-1002L poly (diallyldimethylammonium chloride), Mw: 500,000, manufactured by Senka Co., Ltd.
  • concentration of the coagulant liquid D was 0.05% by mass.
  • a coagulant solution F was prepared by dissolving Unisense FPA-1001L (poly (diallyldimethylammonium chloride), Mw: 500,000, manufactured by Senka Co., Ltd.) in water.
  • the concentration of the flocculant liquid F was 2.0% by mass.
  • Example 1 The glass nonwoven fabric A was immersed in the flocculant liquid A for 1 minute at room temperature (23 ° C.). Next, the glass non-woven fabric A was taken out from the flocculant liquid A and dried at 23 ° C. The blood filter was prepared as described above.
  • Example 2 A blood filter was prepared in the same manner as in Example 1 except that the flocculant liquid A was changed to the flocculant liquid B.
  • Example 3 A blood filter was prepared in the same manner as in Example 1 except that the coagulant liquid A was changed to the coagulant liquid C.
  • Example 4 A blood filter was prepared in the same manner as in Example 1 except that the coagulant solution A was changed to the coagulant solution D.
  • Example 5 A blood filter was prepared in the same manner as in Example 1 except that the flocculant liquid A was changed to the flocculant liquid E.
  • Example 6 A blood filter was prepared in the same manner as in Example 1 except that the glass nonwoven fabric A was changed to each of the glass nonwoven fabrics B to E.
  • Example 10 A blood filter was prepared in the same manner as in Example 1 except that the glass nonwoven fabric A was changed to the glass nonwoven fabric I.
  • Example 11 A blood filter was prepared in the same manner as in Example 1 except that the glass nonwoven fabric A was changed to the glass nonwoven fabric J.
  • Example 12 A blood filter was prepared in the same manner as in Example 11 except that the flocculant liquid A was changed to the flocculant liquid C.
  • Example 3 A blood filter was prepared in the same manner as in Example 1 except that the coagulant liquid A was changed to the coagulant liquid F.
  • Example 6 A blood filter was prepared in the same manner as in Example 1 except that the glass nonwoven fabric A was changed to each of the glass nonwoven fabrics F to H.
  • Z Mass of each glass nonwoven fabric after heating at 500 ° C.
  • the blood filter of the present invention is used, for example, as a blood filter for genetic testing, a blood filter for infectious disease testing, a blood filter for biochemical testing, a blood filter for microbiological testing, and the like.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Geology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Filtering Materials (AREA)

Abstract

La présente invention concerne un filtre sanguin qui est pourvu d'un tissu non tissé en verre et d'un coagulant de cellule sanguine adhérant au tissu non tissé en verre. La valeur de perte de pression du tissu non tissé en verre par rapport à l'épaisseur du tissu non tissé en verre est comprise entre 120 Pa/mm et 1500 Pa/mm et la quantité d'adhérence du coagulant de cellule sanguine par rapport à 100 parties en masse de fibres de verre contenues dans le tissu non tissé de verre est comprise entre 0,1 partie en masse et 6,6 parties en masse.
PCT/JP2019/037009 2018-11-19 2019-09-20 Filtre sanguin WO2020105270A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2018-216341 2018-11-19
JP2018216341 2018-11-19
JP2019-160327 2019-09-03
JP2019160327A JP2020085887A (ja) 2018-11-19 2019-09-03 血液フィルター

Publications (1)

Publication Number Publication Date
WO2020105270A1 true WO2020105270A1 (fr) 2020-05-28

Family

ID=70773224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/037009 WO2020105270A1 (fr) 2018-11-19 2019-09-20 Filtre sanguin

Country Status (1)

Country Link
WO (1) WO2020105270A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048115A1 (fr) * 2021-09-21 2023-03-30 日東紡績株式会社 Agent de séparation de cellules sanguines et méthode de séparation de cellules sanguines l'utilisant

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63177059A (ja) * 1986-10-29 1988-07-21 バイオトラック，インコーポレイティド 血液分離装置及び方法
US5423989A (en) * 1988-05-19 1995-06-13 Chemtrack, Inc. Plasma forming device
JPH09143081A (ja) * 1995-06-09 1997-06-03 Toyobo Co Ltd 血漿分離フィルター、それを用いる血漿分離方法および血漿分離装置
JP2000338103A (ja) * 1999-05-26 2000-12-08 Fujirebio Inc 分離装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63177059A (ja) * 1986-10-29 1988-07-21 バイオトラック，インコーポレイティド 血液分離装置及び方法
US5423989A (en) * 1988-05-19 1995-06-13 Chemtrack, Inc. Plasma forming device
JPH09143081A (ja) * 1995-06-09 1997-06-03 Toyobo Co Ltd 血漿分離フィルター、それを用いる血漿分離方法および血漿分離装置
JP2000338103A (ja) * 1999-05-26 2000-12-08 Fujirebio Inc 分離装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023048115A1 (fr) * 2021-09-21 2023-03-30 日東紡績株式会社 Agent de séparation de cellules sanguines et méthode de séparation de cellules sanguines l'utilisant

Similar Documents

Publication Publication Date Title
US10981096B2 (en) Process for making high efficiency synthetic filter media
CA2767761C (fr) Membranes de purification de l'eau, presentant une resistance amelioree a l'encrassement
KR101930147B1 (ko) 중공사막, 및 중공사막의 제조 방법
TWI643665B (zh) 微多孔膜及其製造方法
JP7250845B2 (ja) 燃料流用の複合媒体
CN110449048A (zh) 一种纳滤膜、制备方法以及染料分离方法
US20120067821A1 (en) Filter Medium For Leukocyte Removal
WO1997022405A1 (fr) Membrane de filtration du type a fibre creuse
TWI657858B (zh) 複合微多孔質膜、其製造方法及使用其的過濾器
Shen et al. Preliminary investigation on hemocompatibility of poly (vinylidene fluoride) membrane grafted with acryloylmorpholine via ATRP
WO2020105270A1 (fr) Filtre sanguin
CN112023731B (zh) 一种高通量低压反渗透膜的制备方法
CN109126205B (zh) 一种油水分离用ps/pmma仿生超疏水膜的制备方法
JP2020085887A (ja) 血液フィルター
JP2015160185A (ja) メンブレンバイオリアクター
JP2014519971A (ja) 液体濾過媒体
TW201942260A (zh) 塗佈組成物以及親水化微多孔膜
TW201836699A (zh) 聚偏二氟乙烯系微多孔膜
JPWO2018030057A1 (ja) 不織布およびその製造方法
JPH07185235A (ja) ろ紙とその製造方法
US20150133286A1 (en) Zwitterionic-Bias Material For Blood Cell Selection
JP2020147701A (ja) 親水性複合多孔質膜
JP2017042691A (ja) 膜分離活性汚泥処理用半透膜用支持体の製造方法
US9695084B2 (en) Preparation for fiberglass air filtration media
KR20130078825A (ko) 정삼투막 및 그 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19887967

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19887967

Country of ref document: EP

Kind code of ref document: A1